Driving a new era of science through traditional and innovative approaches that accelerate development, lower costs, and derisk regulatory pathways.
Equip drug developers with reproducible human-based platforms and analytics to accelerate drug discovery.
Traditional paradigms, NAMs (in-vitro, in-vivo, computational models) deliver scientific insights aligned with 3R principles.
Industry-leading strategic leadership across biology, ADME/PK, toxicology, pathology, translational science, and regulatory disciplines guides every step.
Sponsors gain measurable efficiencies & lower study costs through our curated CRO network & SPECCRO's integrated project management & on-site monitoring.
Accelerate regulatory submissions with confidence and speed through focused and fit-for-purpose studies.
Despite countless therapies, 90% of drugs fail in clinical trials due to non-predictive preclinical models. SPECCRO is changing that.
Each failed candidate costs $2.0- $2.5 Billion.
Backed by scientific advances and recent FDA and EMA reforms, NAMs now have clear regulatory momentum as credible alternatives to animal testing.